CN110432492A - A kind of hypoglycemic nano-clathrate and preparation method thereof - Google Patents
A kind of hypoglycemic nano-clathrate and preparation method thereof Download PDFInfo
- Publication number
- CN110432492A CN110432492A CN201910792497.8A CN201910792497A CN110432492A CN 110432492 A CN110432492 A CN 110432492A CN 201910792497 A CN201910792497 A CN 201910792497A CN 110432492 A CN110432492 A CN 110432492A
- Authority
- CN
- China
- Prior art keywords
- nano
- clathrate
- hypoglycemic
- water
- extracts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002218 hypoglycaemic effect Effects 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 26
- 230000000694 effects Effects 0.000 claims abstract description 22
- 239000000284 extract Substances 0.000 claims abstract description 22
- 240000001080 Grifola frondosa Species 0.000 claims abstract description 21
- 235000007710 Grifola frondosa Nutrition 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 17
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 16
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 16
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 10
- 239000000463 material Substances 0.000 claims abstract description 6
- 239000002253 acid Substances 0.000 claims abstract description 5
- 239000002245 particle Substances 0.000 claims abstract description 3
- 235000018102 proteins Nutrition 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 229920002752 Konjac Polymers 0.000 claims description 8
- 241000222684 Grifola Species 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 108010035532 Collagen Proteins 0.000 claims description 6
- 102000008186 Collagen Human genes 0.000 claims description 6
- 229920001436 collagen Polymers 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 229920001661 Chitosan Polymers 0.000 claims description 5
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 claims description 4
- 229920002581 Glucomannan Polymers 0.000 claims description 4
- 108010073771 Soybean Proteins Proteins 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 229940046240 glucomannan Drugs 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 229940001941 soy protein Drugs 0.000 claims description 4
- 235000005911 diet Nutrition 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000000835 fiber Substances 0.000 claims description 3
- 235000017060 Arachis glabrata Nutrition 0.000 claims description 2
- 244000105624 Arachis hypogaea Species 0.000 claims description 2
- 235000010777 Arachis hypogaea Nutrition 0.000 claims description 2
- 235000018262 Arachis monticola Nutrition 0.000 claims description 2
- 240000008042 Zea mays Species 0.000 claims description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 235000005822 corn Nutrition 0.000 claims description 2
- 230000037213 diet Effects 0.000 claims description 2
- 235000021245 dietary protein Nutrition 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- 235000020232 peanut Nutrition 0.000 claims description 2
- 108010046377 Whey Proteins Proteins 0.000 claims 1
- 102000007544 Whey Proteins Human genes 0.000 claims 1
- 235000021119 whey protein Nutrition 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 18
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 11
- 239000008280 blood Substances 0.000 abstract description 8
- 210000004369 blood Anatomy 0.000 abstract description 8
- 235000013376 functional food Nutrition 0.000 abstract description 5
- 239000008103 glucose Substances 0.000 abstract description 5
- 201000001421 hyperglycemia Diseases 0.000 abstract description 5
- 230000002496 gastric effect Effects 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 4
- 210000002784 stomach Anatomy 0.000 abstract description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 abstract description 3
- 230000003915 cell function Effects 0.000 abstract description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 abstract description 3
- 238000013268 sustained release Methods 0.000 abstract description 3
- 239000012730 sustained-release form Substances 0.000 abstract description 3
- 235000013361 beverage Nutrition 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 abstract description 2
- 238000001802 infusion Methods 0.000 abstract description 2
- 238000010172 mouse model Methods 0.000 abstract description 2
- 239000007787 solid Substances 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 13
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 5
- 210000004051 gastric juice Anatomy 0.000 description 5
- 238000005469 granulation Methods 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 235000010485 konjac Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000004383 Steviol glycoside Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000007908 nanoemulsion Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229930182488 steviol glycoside Natural products 0.000 description 2
- 235000019411 steviol glycoside Nutrition 0.000 description 2
- 150000008144 steviol glycosides Chemical class 0.000 description 2
- 235000019202 steviosides Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000001889 Acid-Base Imbalance Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000222455 Boletus Species 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 241000222640 Polyporus Species 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention discloses a kind of hypoglycemic nano-clathrates and preparation method thereof, belong to technical field of functional food.The present invention acid it is molten add lye neutralize by way of, Effects of Extracts of Grifola frondosa on Active, dietary fiber, protein peptides are prepared into nano-clathrate.Nano-clathrate materials safety of the invention, compatibility are reasonable.And the preparation method and technique of the inclusion compound, operation is simple, reproducibility is good, gained particle or tabletting good appearance, wearability be strong, formability is good.The inclusion compound experiments verify that, have the effect of stomach juice-resistant, sustained release, and in hyperglycemia mouse model, after gastric infusion 2 weeks, the fasting blood-glucose rate of descent of model is 39.5%, can be effectively improved islet beta cell function, reduces blood glucose.The prescription mouthfeel is excellent, can be used as solid beverage or functional food raw material is applied, be widely used in diabetic.
Description
Technical field
The present invention relates to a kind of hypoglycemic nano-clathrates and preparation method thereof, belong to technical field of functional food.
Background technique
Diabetes be it is a kind of due to caused by defect of insulin secretion or insulin action obstacle characterized by hyperglycemia
Metabolic disease.Persistent high blood sugar and long-term metabolic disorder etc. can lead to body tissue's organ, especially eye, kidney, angiocarpy and
The damage of nervous system and its dysfunction and failure.Serious person can cause dehydration, electrolyte disturbance and acid-base imbalance etc.
Acute complications ketoacidosis and Hyperosmotic coma.With people's living condition it is continuous improvement and improve, material life it is rich
Rich diversification, allegro life in addition, so that the multiple illness patient numbers such as diabetes sharply increase.
Modern medicine, mainly from treatment angle, pointedly uses oral or injection hypoglycemic to the control of diabetes
The modes such as medicine, insulin, but these drugs easily cause patient's hypoglycemia and islet beta cell function failure and other side effects,
And it is difficult to prevent or prevent the appearance of chronic complicating diseases, the specific chronic complicating diseases of especially certain diabetes completely.Drink
Food has a far reaching influence to diabetic duration, the control that there is reasonable supplement the food of blood sugar reducing function to not only contribute to diabetic condition,
Be conducive to the nutrient of patient's body simultaneously.Therefore, finding and developing safe and effective function of blood sugar reduction food is to study at present
One of hot spot.
Grifola frondosus Boletus frondosus Dicks, the fructification of On Polyporaceae polyporus frondosus, as one kind
Rare dietotherapeutic bacterium is rich in hundreds of active polysaccharides, steroid, phenols, triterpenes isoreactivity substance.Studies have shown that from
The Grifola Frondosa sporophore powder manually cultivated flows back through ethanol ether, water mentions, alcohol precipitation, dry that Thick many candies can effectively inhibit α-sugar
Glycosides enzymatic activity reduces the blood glucose level of hyperglycemia mouse.But be mostly used the organic solvents such as ether in literature research and extract, it is residual
It stays solvent to be difficult to remove, is not suitable for food development.Grifola frondosus functional product common at present is mainly with oral administration solution or tabletting
Based on candy, and there are gastric juice easily by acid degradation for main composition-polysaccharide that it contains, and molecular weight causes greatly absorption difference etc. to be asked
Topic, therefore there is researcher to be prepared into nano-emulsion etc. also to improve bioavilability, but nano-emulsion formula composition, preparation process
It is complex.In view of above, the present invention is directed to invent the high grifola frondosus functional food of a kind of simple process, bioavilability.
Summary of the invention
In order to solve the above technical problems, the present invention provides a kind of hypoglycemic nano-clathrate, with stomach juice-resistant, sustained release
Effect, and preparation process is simple, reproducible, inclusion compound major function raw material of the invention is Effects of Extracts of Grifola frondosa on Active, diet fibre
Peacekeeping protein.For diabetes patient's three-many-one-little symptom, functional Effects of Extracts of Grifola frondosa on Active is provided and is aided with adequate nutrition, with slow
Subtract diabetes patient's clinical nutrition situation and symptom.
The first purpose of the invention is to provide a kind of preparation methods of hypoglycemic nano-clathrate, including walk as follows
It is rapid: water insoluble dietary fiber being dissolved in acid solution, Effects of Extracts of Grifola frondosa on Active, water-soluble dietary fiber and protein peptides are added and stir
Mix, after mixing, be added in system in lye and, drying and crushing obtains the hypoglycemic nano-clathrate.
Further, the mass fraction of Effects of Extracts of Grifola frondosa on Active is not less than 10% in the nano-clathrate.
Further, the Effects of Extracts of Grifola frondosa on Active, water-soluble dietary fiber, water insoluble dietary fiber, protein peptides
Mass ratio is 10~35:4~6:4~6:1~5.
Further, the water-soluble dietary fiber is konjaku glucomannan, and water insoluble dietary fiber is chitosan
Or chitosan oligosaccharide.
Further, the protein peptides are vegetable protein sources protein peptides or animal protein sources protein peptides.
Further, the protein peptides are Soyprotein peptide, corn protein peptide, peanut protein peptide, collagen peptide, cream
One of albumin peptide or more than one combinations.
Further, the Effects of Extracts of Grifola frondosa on Active is prepared as follows to obtain: grifola frondosus powder is taken, water is added:
The alcoholic solution that alcohol volume ratio is 2~4:1 carries out refluxing extraction, is dried to obtain Effects of Extracts of Grifola frondosa on Active.
Further, the acid solution is one of glacial acetic acid, hydrochloric acid or more than one combinations.
Further, the lye is sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium carbonate, potassium carbonate, bicarbonate
One of sodium or more than one combinations.
Further, alkali additional amount is stoichiometrically calculated as final solution in pH=6.5~7.5.
Further, the preparation method further includes mixing smashed nano-clathrate with auxiliary material, is prepared into
Grain or tabletting.
Further, the auxiliary material includes 0.1~1 part of steviol glycoside, 0.01~0.1 part of natural essence.
A second object of the present invention is to provide the hypoglycemic nano-clathrates that the method is prepared.
Third object of the present invention is to provide food, drug or health cares comprising the hypoglycemic nano-clathrate
Product.
The beneficial effects of the present invention are:
The present invention provides a kind of nano-clathrate with function of blood sugar reduction, the nano-clathrate materials safeties, compatibility
Rationally.And the preparation method and technique of the inclusion compound, operation is simple, reproducibility is good, gained particle or tabletting good appearance,
Wearability is strong, formability is good.The inclusion compound experiments verify that, have the effect of stomach juice-resistant, sustained release, and in hyperglycemia mouse model
In, after gastric infusion 2 weeks, the fasting blood-glucose rate of descent of model is 39.5%, can be effectively improved islet beta cell function, reduces blood
Sugar.The prescription mouthfeel is excellent, can be used as solid beverage or functional food raw material is applied, be widely used in diabetic.
Detailed description of the invention
Fig. 1 is the transmission electron microscope picture of hypoglycemic nano-clathrate.
Specific embodiment
The present invention will be further explained below with reference to the attached drawings and specific examples, so that those skilled in the art can be with
It more fully understands the present invention and can be practiced, but illustrated embodiment is not as a limitation of the invention.
Embodiment 1: grifola frondosus raw material extracts
10 parts of Grifola Frondosa sporophore powder manually cultivated are taken, 30 parts of water: the ethanol water of ethyl alcohol=3:1 (volume ratio) are added
Solution carries out refluxing extraction 2h, is dried to obtain extract.
Embodiment 2: inclusion compound preparation process
5 parts of chitosan are taken, is dissolved in 0.1% acetum of 500mL, 35 parts of Effects of Extracts of Grifola frondosa on Active, konjak portuguese gansu polyose is added
Sugared 5 parts, 1 part of collagen peptide, are uniformly mixed, and 1% sodium bicarbonate solution is added under stirring, until pH=7,
It is freeze-dried 30h, is placed under transmission electron microscope and observes, partial size is about 20 ± 5nm, and the piece of 1g/ piece is made in granulation, drying, tabletting
Agent.
Embodiment 3: inclusion compound tabletting preparation process
5 parts of chitosan are taken, is dissolved in 0.1% acetum of 500mL, 20 parts of Effects of Extracts of Grifola frondosa on Active, konjak portuguese gansu polyose is added
Sugared 5 parts, 1 part of collagen peptide, are uniformly mixed, and under stirring 1% sodium bicarbonate solution are added until pH=7,
Freeze-drying 30 hours, after crushing, with 0.1 part of steviol glycoside, 0.05 part of natural essence mixing, granulation, drying, tabletting are made
The tablet of 1g/ piece.Gained tabletting gloss is obvious, good mouthfeel, and smell is pleasant.
Embodiment 4: inclusion compound preparation
5 parts of chitosan oligosaccharide are taken, is dissolved in 0.1% acetum of 500mL, 20 parts of Effects of Extracts of Grifola frondosa on Active, konjak portuguese gansu polyose is added
Sugared 5 parts, 1 part of Soyprotein peptide, are uniformly mixed, and 1% sodium bicarbonate solution is added under stirring, until pH=7,
Freeze-drying 30 hours, granulation, drying, tabletting, is made the tablet of 1g/ piece.
Embodiment 5: inclusion compound preparation
5 parts of chitosan are taken, is dissolved in 500mL0.1% hydrochloric acid solution, 20 parts of Effects of Extracts of Grifola frondosa on Active, konjak portuguese gansu polyose is added
Sugared 5 parts, 5 parts of Soyprotein peptide, are uniformly mixed, and 1% sodium bicarbonate solution is added under stirring, until pH=7,
Freeze-drying 30 hours, granulation, drying, tabletting, is made the tablet of 1g/ piece.
Comparative example 1:
35 parts of Effects of Extracts of Grifola frondosa on Active, 5 parts of chitosan oligosaccharide, 5 parts of konjaku glucomannan, 1 part of collagen peptide are taken, is stirred
Even, the tablet of 1g/ piece is made in granulation, drying, tabletting.
Comparative example 2:
35 parts of Effects of Extracts of Grifola frondosa on Active, 5 parts of chitosan oligosaccharide, 5 parts of konjaku glucomannan, 1 part of collagen peptide are taken, and stevia rebaudianum is added
0.1 part of glucosides, 0.05 part of natural essence, are uniformly mixed, pelletize, dry, tabletting, the tablet of 1g/ piece is made.
Embodiment 6: gastric juice resistant evaluation
The gastric juice resistant performance of test distinct methods preparation resulting product in simulation simulated gastric fluid.
Simulated gastric fluid formula: taking mass fraction is the hydrochloric acid 1.0mL of 0.1mol/L, is diluted with distilled water and is adjusted to its pH value
2.0.Then pepsin 0.01g/mL is added, it is spare with miillpore filter degerming after being uniformly dissolved.
1 is taken to be added to above-mentioned artificial in-vitro simulated gastric juice respectively product made from embodiment 1-4 and comparative example 1-2
In, every 1h takes a sample, using protein concentration in Coomassie Brilliant Blue test sample, is indicated with the OD at 595nm, each sample
Product retest 3 times.From the data in table 1, it can be seen that the OD value of several samples solution at the beginning is close, there is certain background to absorb.
Over time, comparative example 1 is disintegrated in 30min completely with tabletting made from comparative example 2.And the product of embodiment 1 is arranged in stomach
(8.0 ± 0.32) % is only released in empty time (4h).
1 inclusion compound tabletting artificial gastric juice resistance's property of table
Embodiment 7: inclusion compound hypoglycemic effect evaluation
The inclusion compound tabletting that Example 3 is prepared, establishes zoic model with hyperglycemia, is divided into model group and inclusion compound
Group, model group stomach-filling physiological saline, inclusion compound group stomach-filling inclusion compound suspension, continuous gavage are administered 14 days, monitor mouse daily
Weight, amount of drinking water and dietary amount, blood glucose value.The result shows that the three-many-one-little symptom of inclusion compound group diabetes mice significantly improves,
And hypoglycemic effect is significant.
Separately according to literature method: taking the Grifola Frondosa sporophore powder manually cultivated, ethyl alcohol: ether=3:1 (volume is added
Than) ethanol ether solution carry out refluxing extraction, then be added water carry out water mention, reuse ethyl alcohol carry out alcohol precipitation, be dried to obtain
Extract.Then inclusion compound tabletting is prepared according to the method for embodiment 3, carries out hypoglycemic effect evaluation, is obtained with 3 method of embodiment
Inclusion compound tabletting hypoglycemic effect it is suitable.
Embodiment described above is only to absolutely prove preferred embodiment that is of the invention and being lifted, protection model of the invention
It encloses without being limited thereto.Those skilled in the art's made equivalent substitute or transformation on the basis of the present invention, in the present invention
Protection scope within.Protection scope of the present invention is subject to claims.
Claims (10)
1. a kind of preparation method of hypoglycemic nano-clathrate, which comprises the steps of: by water-insoluble diet
Fiber is dissolved in acid solution, Effects of Extracts of Grifola frondosa on Active, water-soluble dietary fiber and protein peptides stirring is added, after mixing, in body
Lye is added in system to neutralize, drying and crushing obtains the hypoglycemic nano-clathrate.
2. the method according to claim 1, wherein in the nano-clathrate Effects of Extracts of Grifola frondosa on Active quality
Score is not less than 10%.
3. the method according to claim 1, wherein the Effects of Extracts of Grifola frondosa on Active, water-soluble dietary fiber, water
Insoluble diedairy fiber, protein peptides mass ratio be 10~35:4~6:4~6:1~5.
4. the method according to claim 1, wherein the water-soluble dietary fiber be konjaku glucomannan,
Water insoluble dietary fiber is chitosan or chitosan oligosaccharide.
5. the method according to claim 1, wherein the protein peptides be Soyprotein peptide, corn protein peptide,
One of peanut protein peptide, collagen peptide, whey protein peptide or more than one combinations.
6. the method according to claim 1, wherein the Effects of Extracts of Grifola frondosa on Active is prepared as follows
To: grifola frondosus powder is taken, water is added: the alcoholic solution that alcohol volume ratio is 2~4:1 carries out refluxing extraction, is dried to obtain grifola frondosus and mentions
Take object.
7. the method according to claim 1, wherein lye additional amount is stoichiometrically calculated as final solution is in
PH=6.5~7.5.
8. the method according to claim 1, wherein the preparation method further includes wrapping smashed nanometer
It closes object to mix with auxiliary material, is prepared into particle or tabletting.
9. a kind of hypoglycemic nano-clathrate that the described in any item methods of claim 1-8 are prepared.
10. a kind of food, drug or health care product comprising hypoglycemic nano-clathrate as claimed in claim 9.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910792497.8A CN110432492A (en) | 2019-08-26 | 2019-08-26 | A kind of hypoglycemic nano-clathrate and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910792497.8A CN110432492A (en) | 2019-08-26 | 2019-08-26 | A kind of hypoglycemic nano-clathrate and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110432492A true CN110432492A (en) | 2019-11-12 |
Family
ID=68437753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910792497.8A Pending CN110432492A (en) | 2019-08-26 | 2019-08-26 | A kind of hypoglycemic nano-clathrate and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110432492A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112079937A (en) * | 2020-08-10 | 2020-12-15 | 吉林省桦树茸国际健康产业集团有限公司 | Extraction and inclusion of polysaccharide and polypeptide for reducing blood sugar in Inonotus obliquus and application of polysaccharide and polypeptide in biscuit |
| WO2024029392A1 (en) * | 2022-08-03 | 2024-02-08 | サントリーホールディングス株式会社 | Oral composition, and method for suppressing bitterness derived from ergothioneine or salt thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1554330A (en) * | 2003-12-22 | 2004-12-15 | 天津大学 | Konjaku gluocomannan-calcium alginate microball for carrying medicine and preparing method |
| CN1742628A (en) * | 2004-09-03 | 2006-03-08 | 王锦 | Food cellulose powder for diabets nutrition therapy |
| CN103467752A (en) * | 2013-09-09 | 2013-12-25 | 浙江大学 | Method for dissolving chitosan through combined use of acid and alkali |
| CN104116071A (en) * | 2014-05-29 | 2014-10-29 | 武汉思维特食品有限公司 | Royal jelly, litchi chinensis seed and grifola frondosa microcapsule and preparation method thereof |
| CN105055372A (en) * | 2015-08-18 | 2015-11-18 | 华中农业大学 | Method for preparing carboxymethyl konjac glucomannan nano drug carrying microspheres |
| CN106551229A (en) * | 2016-11-15 | 2017-04-05 | 上海市农业科学院 | A kind of compound edible mushroom solid beverage |
| WO2019068466A1 (en) * | 2017-10-05 | 2019-04-11 | Pharmactive Biotech Products, S.L. | Dietary fiber composition for protecting bioactive compounds during the physiological digestion process |
-
2019
- 2019-08-26 CN CN201910792497.8A patent/CN110432492A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1554330A (en) * | 2003-12-22 | 2004-12-15 | 天津大学 | Konjaku gluocomannan-calcium alginate microball for carrying medicine and preparing method |
| CN1742628A (en) * | 2004-09-03 | 2006-03-08 | 王锦 | Food cellulose powder for diabets nutrition therapy |
| CN103467752A (en) * | 2013-09-09 | 2013-12-25 | 浙江大学 | Method for dissolving chitosan through combined use of acid and alkali |
| CN104116071A (en) * | 2014-05-29 | 2014-10-29 | 武汉思维特食品有限公司 | Royal jelly, litchi chinensis seed and grifola frondosa microcapsule and preparation method thereof |
| CN105055372A (en) * | 2015-08-18 | 2015-11-18 | 华中农业大学 | Method for preparing carboxymethyl konjac glucomannan nano drug carrying microspheres |
| CN106551229A (en) * | 2016-11-15 | 2017-04-05 | 上海市农业科学院 | A kind of compound edible mushroom solid beverage |
| WO2019068466A1 (en) * | 2017-10-05 | 2019-04-11 | Pharmactive Biotech Products, S.L. | Dietary fiber composition for protecting bioactive compounds during the physiological digestion process |
Non-Patent Citations (3)
| Title |
|---|
| 傅美超等: "《药用辅料学》", vol. 1, 31 October 2008, 中国中医药出版社, pages: 285 * |
| 张宏其等: "《脊柱结核手术学：普及版》", vol. 1, 31 July 2018, 广东科技出版社, pages: 30 * |
| 郭剑霞: "《多不饱和脂肪酸的分离纯化及功能研究》", vol. 1, 31 December 2018, 中国轻工业出版社, pages: 158 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112079937A (en) * | 2020-08-10 | 2020-12-15 | 吉林省桦树茸国际健康产业集团有限公司 | Extraction and inclusion of polysaccharide and polypeptide for reducing blood sugar in Inonotus obliquus and application of polysaccharide and polypeptide in biscuit |
| WO2024029392A1 (en) * | 2022-08-03 | 2024-02-08 | サントリーホールディングス株式会社 | Oral composition, and method for suppressing bitterness derived from ergothioneine or salt thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101919530B (en) | Tea and preparation method thereof | |
| CN107156587A (en) | Active probiotic solid beverage and its treatment diabetes B in apply | |
| CN104739921B (en) | A kind of prescription lozenge and preparation method thereof for alleviating visual fatigue | |
| CN109221898A (en) | A kind of grain dust and its preparation method and application containing xylo-oligosaccharide | |
| CN103861086A (en) | Preparation method of bitter gourd peptide arabinose composite tablet | |
| CN108430479A (en) | Beta-1,3-dextran is used to adjust immune function and treat the purposes of intestinal inflammatory | |
| CN106605822A (en) | Composition facilitating reducing of blood sugar and preparation method of composition | |
| Wu et al. | Hypoglycemic effect of okra aqueous extract on streptozotocin-induced diabetic rats | |
| CN110432492A (en) | A kind of hypoglycemic nano-clathrate and preparation method thereof | |
| CN107319553A (en) | A kind of health products of auxiliary hyperglycemic strengthen immunity and preparation method thereof | |
| CN105661547A (en) | Probiotics and Bombyx mori compounded diabetic patient nutritional supplement | |
| CN102448479B (en) | A novel antidiabetic furostanolic saponin rich (fsr) fraction from fenugreek seeds | |
| CN102698271A (en) | Hypoglycemic drug composition and application of hypoglycemic drug composition | |
| CN102552299B (en) | Application of dioscin in preparing medicament for preventing and treating diabetes mellitus | |
| CN103281914B (en) | Purification of soluble mannan compositions and using method thereof for dietary supplement | |
| CN110432500A (en) | A kind of prebiotic compositions and preparation method and purposes containing inulin | |
| CN105343585B (en) | A kind of corn stigma effervescent tablet and preparation method thereof | |
| CN107242551A (en) | A kind of cancer rehabilitation type Medical Nutritional composition and preparation method thereof | |
| JP2018070568A (en) | Nonalcoholic fatty liver disease treating or preventing agent and food for preventing nonalcoholic fatty liver disease | |
| CN110074392A (en) | A kind of Antialcoholic liver-protecting nourishing the stomach shield intestines composition and preparation method thereof | |
| CN107537028B (en) | Formula for simultaneously assisting in reducing blood sugar and blood pressure and preparation method thereof | |
| CN109123414A (en) | A kind of nutraceutical and preparation method thereof of insulin resistance syndrome crowd | |
| CN109700028A (en) | Postprandial blood sugar suitable for I crowd of visible peristalsis visible intestinal peristalsis adjusts the dietary composition with prevention | |
| CN101912407A (en) | Weight-reducing and lipid-lowering composition | |
| CN101564511B (en) | Natural protein product for treating diabetes and manufacture method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191112 |